Stock explainer / Pharmaceuticals / Reviewed 11 October 2026
Novo Nordisk stock, explained for beginners
The short answer
Novo Nordisk, based in Denmark, develops medicines for diabetes and obesity, as well as treatments for rare diseases.
Investing involves risk and you can lose money. This page explains general ideas; it is not personal financial, tax or investment advice.
How Novo Nordisk makes money
- Selling diabetes treatments such as insulin and GLP-1 medicines
- Selling obesity medicines
- Treatments for rare blood and hormone disorders
Main strengths
- Long experience in diabetes care
- Strong demand for its newer medicines
- Global manufacturing and distribution
Main risks
- Growing competition in obesity treatments
- Pressure on medicine prices from governments and insurers
- Patents expire over time and production must keep up with demand
Five questions to ask about Novo Nordisk
These match Mesodian's five core scores. Members see each score, updated, with the factors behind it.
- Quality
- How healthy are its margins and cash flow?
- Growth
- Can demand for its newer medicines keep growing?
- Value
- How does its price compare with expected earnings?
- Sentiment
- How do investors view competition in obesity medicines?
- Risk
- How exposed is it to pricing rules and trial results?
This explainer is general education about a well-known company. It is not a recommendation to buy, sell or hold NVO. Check the company's latest reports before making decisions.
Keep going
Learn as you invest, with Mesodian.
Lessons, five plain-English scores and a clear view of your portfolio. Research is $9.99 a month; Premium, with broker connection and portfolio tracking, is $14.99.